PATIENTS DRIVE US. AND NOT JUST OUR VENTURES, IT DRIVES OUR VALUES AND MISSION AS A COMPANY
It’s at the core of everything we do and what motivates us in our work. However, it is very hard to measure if a patient is happy. Therefore, we have integrated questions from the broadly used EQ-5D, an instrument which evaluates the generic quality of life, this questionnaire has questions about the change in mobility, selfcare opportunities, usual activities, pain and discomfort, and anxiety.
Since our ventures in the diagnostics space have no direct impact on these factors, we added one question: “Will the product have an impact on the life expectancy of the patient?”. Eventually, most of our ventures will perform an objective study towards their added value (and corresponding costs) in a Health Technology Assessment (HTA).
It is therefore not surprising that all of our ventures have the promise to positively impact the quality of life of patients globally. In 2022, our ventures have reached over 110.000 patients with their solutions. And forward looking, our current portfolio companies have the potential to reach over 500 million patients in 2030.
One of our ventures that has a very positive impact on patients is Concord Neonatal. Thanks to the Concord birth trolley, there is a higher chance a premature baby will survive the birth. Next to that, there is a lower chance that the baby will be severely disabled.